Diabetes Management: Blood Glucose Monitoring Devices Market
Diabetes Management: Blood Glucose Monitoring Devices Market
$4,750.00
According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Report Highlights
- Global sales of blood glucose monitoring devices, which include both traditional handheld blood glucose meters (BGMs), new continuous glucose monitoring systems (CGMs) and disposable sensors/supplies/accessories, are expected to increase at a double-digit CAGR of approximately 11%, from nearly $8bn in 2018 to approximately $13bn in 2023
- Growth will be led by phenomenal sales in the CGMs segment
- By 2021 the CGM segment is expected to surpass the BGMs segment in revenue volume, and by 2023 nearly triple the size of the BGMs market
- The steady, rather precipitous decline in the BGMs segment is due to continued downward pricing pressure/extreme price competition, lowered test-strip reimbursement, and market saturation of numerous lower-cost BGMs, among other factors
- The major suppliers of blood glucose monitoring products in 2018 included: Abbott, Roche, Ascensia Diabetes Care, Dexcom, LifeScan, Medtronic, and dozens of smaller competitors (eg Senseonics, Nemaura Medical)
- The revolutionary ability of CGMs to monitor patients 24/7 without painful fingersticks, improve glucose control and lessen insulin dosing errors in type 1 and (insulin-dependent) type 2 diabetes patients on MDI therapy is resulting in substantial growth of revenues for Abbott, Dexcom, and Medtronic; the financial and marketing strength of these companies is making it difficult for small and emerging startups to gain a foothold, but significant innovation is taking place
- Overall, there is a strong need to lessen patient burden, pain, and device complexity, while improving accuracy, glycemic control, lowering healthcare costs, and quality of life
- CGMs are addressing these needs and new and future products will be even more affordable, less invasive, convenient, comfortable/discreet, accurate, and longer-wear.
Key Questions Answered
- An overview of diabetes and prevalence
- A discussion of BGM and CGM technologies, product portfolios, and pipelines
- Emerging startups and technologies
- In-depth market and competitive analyses, including market drivers/limiters, 5-year market forecasts by segment and region, and global/regional market share
- An overview of companies, financials, and strategic growth plans
Overview
According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.
Blood glucose monitoring is essential for people with diabetes to lower the risk of complications. It is particularly important for those with type 1 diabetes, but also in people with type 2 diabetes who frequently administer insulin and/or suffer from symptomatic blood sugar fluctuations.
Blood glucose monitoring devices include both traditional handheld blood glucose meters (BGMs) used by patients at home and by healthcare practitioners at the point-of-care, and new sophisticated continuous glucose monitoring systems (CGMs) used by type 1 and insulin-dependent type 2 diabetics.
Valued at nearly $8bn in 2018, the global Blood Glucose Monitoring Devices (BGMDs) Market is growing at a fast pace—at a compound annual growth rate (CAGR) of approximately 11%—due to the phenomenal sales growth of new revolutionary CGMs, such as Abbott’s FreeStyle Libre and Dexcom’s G6 CGM. The market is expected to total nearly $13bn by 2023. Growth of CGMs will be offset by a steady decline in the BGMs segment due to continued extreme price competition/downward pricing pressure, lowered test-strip reimbursement, and market saturation of lower-cost meters, among other factors.
The overall BGMDs market is being driven by several positive factors, including:
- strong demand for discreet, accurate CGM devices that provide convenient blood glucose monitoring 24/7 and eliminate frequent/cumbersome and painful fingersticks
- steadily increasing awareness and adoption of new, next-generation CGMs (by Abbott and Dexcom) driven by strong sales/marketing/advertising and physician referrals
- solid clinical outcomes due to the ability to improve the accuracy of insulin delivery and improve glycemic control or time-in-range (TIR) via continuous (24/7) glucose monitoring
- the ability to integrate lucrative CGM sensors into fast-growing next-generation hybrid closed-loop insulin pump systems (eg MiniMed 670G, Tandem’s t:slim, and future pump systems; see below Insulin Pumps report)
- better patient awareness and physician understanding of glucose trends and impact of diet/medication/exercise/lifestyle factors due to the use of smartphone-driven digital health coaching apps, resulting in improved diabetes management
- ability to lower overall healthcare costs
- solid reimbursement
- low CGM market penetration (due to newness of technology), leaving much room for market growth in a large and expanding diabetes population
- sales of lucrative recurring CGM disposables (eg sensors) and accessories.
This comprehensive medical market and technology report provides:
- prevalence of diabetes
- BGM/CGM product portfolios and technical innovations
- product pipelines/emerging technologies/startups
- trends and opportunities
- market drivers and limiters
- market and competitive analysis—including 5-year global and regional market forecasts, global/regional market share (2018), company overview, financials, and strategic growth plans.
Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2018-23 time period.
Contents
Executive Summary……………………………………………………………………………………………….. ES-1
i. Diabetes overview………………………………………………………………………………………………..ES-1
ii. Blood glucose monitoring technology ……………………………………………………………………ES-3
iii. Global blood glucose monitoring devices market……………………………………………………ES-4
iv. Competition……………………………………………………………………………………………………….ES-7
v. Methodology………………………………………………………………………………………………………ES-8
vi. Bibliography …………………………………………………………………………………………………….ES-10
Exhibit ES-1: Blood glucose monitoring device sales by product segment, combined market forecast ($m), 2018-23 ……………………………………………………………. ES-5
1. Diabetes Overview ………………………………………………………………………………………………. 1-1
1.1 Prevalence………………………………………………………………………………………………………… 1-1
1.2 Diabetes defined……………………………………………………………………………………………….. 1-1
1.2.1 Symptoms………………………………………………………………………………………….. 1-2
1.2.2 Complications …………………………………………………………………………………….. 1-4
1.2.3 Diagnosis and treatment………………………………………………………………………. 1-4
1.2.4 Cost of diabetes………………………………………………………………………………….. 1-6
1.3 Bibliography ……………………………………………………………………………………………………… 1-7
2. Blood Glucose Monitoring Devices …………………………………………………………………………. 2-1
2.1 Blood glucose meters…………………………………………………………………………………………. 2-1
2.1.1 Abbott……………………………………………………………………………………………….. 2-9
2.1.2 Ascensia Diabetes Care………………………………………………………………………. 2-10
2.1.3 LifeScan/Platinum Equity……………………………………………………………………. 2-13
2.1.4 Roche ………………………………………………………………………………………………. 2-20
2.1.5 Livongo…………………………………………………………………………………………….. 2-22
2.1.6 One Drop/Apple Watch ……………………………………………………………………… 2-23
2.2 Continuous blood glucose monitoring systems……………………………………………………. 2-25
2.2.1 Abbott……………………………………………………………………………………………… 2-29
2.2.2 Dexcom ……………………………………………………………………………………………. 2-39
2.2.3 Medtronic ………………………………………………………………………………………… 2-46
2.3 New or emerging wearable blood glucose monitoring patches……………………………… 2-52
2.3.1 Medtronic: glucose-sensing patch……………………………………………………….. 2-52
2.3.2 Nemaura Medical………………………………………………………………………………. 2-52
2.3.3 Senseonics………………………………………………………………………………………… 2-57
2.3.4 Verily ………………………………………………………………………………………………. 2-62
2.4 Diabetes monitoring mobile apps………………………………………………………………………. 2-64
2.5 Bibliography ……………………………………………………………………………………………………. 2-65
Exhibit 2-1: Accuracy of blood glucose meters – top 8 with lowest MARD ……………………… 2-3
Exhibit 2-2: Selected blood glucose meter brands by manufacturer………………………………. 2-4
Exhibit 2-3: Selected blood glucose meters and features…………………………………………….. 2-5
Exhibit 2-4: The FreeStyle Lite ………………………………………………………………………………… 2-9
Exhibit 2-5: The Contour NEXT One and Contour Diabetes app …………………………………… 2-11
Exhibit 2-6: The Contour NEXT Link 2.4…………………………………………………………………… 2-12
Exhibit 2-7: OneTouch Verio Flex meter with OneTouch Reveal app and OneTouch Verio meter………………………………………………………………………… 2-15
Exhibit 2-8: OneTouch Reveal Plus powered by Welldoc’s BlueStar intelligent diabetes coaching technology ………………………………………………………………. 2-17
Exhibit 2-9: Welldoc’s BlueStar diabetes AI-driven smart app…………………………………….. 2-18
Exhibit 2-10: The new Accu-Chek Guide, Guide me, and mySugr app…………………………….. 2-21
Exhibit 2-11: One Drop Mobile app, glucose meter/accessories, and the Apple Watch …….. 2-24
Exhibit 2-12: Selected continuous glucose monitoring systems by manufacturer…………….. 2-26
Exhibit 2-13: Selected continuous glucose monitoring systems and features………………….. 2-27
Exhibit 2-14: The FreeStyle Libre 14-day CGM System ………………………………………………… 2-32
Exhibit 2-15: The LibreLink app……………………………………………………………………………….. 2-35
Exhibit 2-16: The Dexcom G6 CGM System with extended 10-day sensor ………………………. 2-41
Exhibit 2-17: Dexcom CLARITY diabetes management software …………………………………… 2-43
Exhibit 2-18: The Guardian Connect CGM System with Sugar.IQ app …………………………….. 2-49
Exhibit 2-19: The iPro2 Professional CGM system with CareLink iPro software ……………….. 2-51
Exhibit 2-20: The SugarBEAT system………………………………………………………………………… 2-53
Exhibit 2-21: How the SugarBEAT draws glucose from interstitial fluid ………………………….. 2-54
Exhibit 2-22: Senseonic’s Eversense Continuous Glucose Monitoring System and insertion procedure ……………………………………………………………………………. 2-58
Exhibit 2-23: Verily Lifesciences’ investigational glucose-measuring contact lens ……………. 2-63
3. Market Analysis…………………………………………………………………………………………………… 3-1
3.1 Blood glucose monitoring devices market…………………………………………………………….. 3-1
3.1.1 Market forecast: global………………………………………………………………………… 3-1
3.1.2 Market forecast: by region and segment ……………………………………………….. 3-5
3.1.3 US market ………………………………………………………………………………………….. 3-8
3.1.4 Five major EU markets…………………………………………………………………………. 3-8
3.1.5 Japanese market…………………………………………………………………………………. 3-9
3.1.6 Rest of the world market……………………………………………………………………… 3-9
3.1.7 Market drivers and limiters ………………………………………………………………… 3-10
3.2 Competitive analysis………………………………………………………………………………………… 3-11
3.2.1 Market share: global/combined ………………………………………………………….. 3-12
3.2.2 Market share: by segment………………………………………………………………….. 3-13
3.2.3 Market share: by region……………………………………………………………………… 3-17
3.3 Corporate profiles……………………………………………………………………………………………. 3-19
3.3.1 Abbott……………………………………………………………………………………………… 3-19
3.3.2 Ascensia Diabetes Care………………………………………………………………………. 3-21
3.3.3 Dexcom ……………………………………………………………………………………………. 3-23
3.3.4 Medtronic ………………………………………………………………………………………… 3-28
3.3.5 Nemaura Medical………………………………………………………………………………. 3-31
3.3.6 Roche ………………………………………………………………………………………………. 3-33
3.3.7 Senseonics………………………………………………………………………………………… 3-36
3.4 Bibliography ……………………………………………………………………………………………………. 3-39
Exhibit 3-1: Blood glucose monitoring device sales by product segment, combined market forecast ($m), 2018-23……………………………………………………………….. 3-2
Exhibit 3-2: Blood glucose monitoring devices market, forecast sales by region ($m), 2018-23 ……………………………………………………………………………………………… 3-6
Exhibit 3-3: Blood glucose monitoring device sales by product segment and region, combined market forecast ($m), 2018-23…………………………………………………. 3-7
Exhibit 3-4: Combined blood glucose monitoring devices market, global share by supplier ($m), 2018 ………………………………………………………………………… 3-12
Exhibit 3-5: Blood glucose meters market, global share by supplier ($m), 2018 …………….. 3-13
Exhibit 3-6: Continuous glucose monitoring systems market, global share by supplier ($m), 2018 ………………………………………………………………………… 3-15
Exhibit 3-7: Combined blood glucose monitoring devices market, estimated share by supplier and region, 2018………………………………………………………………… 3-18
Exhibit 3-8: Abbott, revenues by segment, FY2018 …………………………………………………… 3-21
Exhibit 3-9: Dexcom, revenues by segment, FY2018 …………………………………………………. 3-25
Exhibit 3-10: Medtronic, revenues by segment, FY2019………………………………………………. 3-31
Exhibit 3-11: Roche, revenues by segment, FY2018 ……………………………………………………. 3-35
Exhibit 3-12: Senseonics, revenues by segment, FY2018……………………………………………… 3-37
Appendix A: company listing
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Human Papillomavirus (HPV) KOL Interview – US, Midwest 
Sign up to the